1-7 of 7
Tom Liu
Close
Sort by
Journal Articles

Retrospective Real-World Analysis of Baseline Characteristics and Posttreatment Hematologic Outcomes in Patients with Myelofibrosis Receiving Ruxolitinib

Andrew T. Kuykendall, Mirko Fillbrunn, Tom Liu, Adina Zhang, Ryan Simpson, Kelesitse Phiri, Gautam Sajeev, James Signorovitch
Journal: Blood
Blood (2023) 142 (Supplement 1): 6399.
https://doi.org/10.1182/blood-2023-181137
Published: 2023
Journal Articles

Estimating Transfusion-Related Medical Costs and Associated Time Burden in Patients with Myelofibrosis: A Comparison of Momelotinib Vs Ruxolitinib Based on Simplify-1

Lucia Masarova, Tom Liu, Mirko Fillbrunn, Weilong Li, Gautam Sajeev, Sumati Rao, Boris Gorsh, James Signorovitch
Journal: Blood
Blood (2023) 142 (Supplement 1): 4571.
https://doi.org/10.1182/blood-2023-181185
Published: 2023
Journal Articles

Anemia and Transfusion Dependency Are Important Prognostic Factors for Overall Survival in Patients with Myelofibrosis: Results of a Real-World Analysis of Medicare Patients

Aaron T. Gerds, Ruben A. Mesa, Joseph Tkacz, Laura Moore-Schiltz, Jill Schinkel, Kelesitse Phiri, Tom Liu, Boris Gorsh
Journal: Blood
Blood (2023) 142 (Supplement 1): 6418.
https://doi.org/10.1182/blood-2023-178012
Published: 2023
Journal Articles

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik
Journal: Blood
Blood (2023) 142 (Supplement 1): 1826.
https://doi.org/10.1182/blood-2023-177784
Published: 2023
Journal Articles

Real-World Testing Patterns for Risk Assessment and Implications on the Adoption of Novel Therapeutics in Chronic Lymphocytic Leukemia: IGHV Mutation Status, FISH Cytogenetic, and Immunophenotyping

Asher Chanan-Khan, Keri Yang, Tom Liu, Todd Zimmerman, Boxiong Tang, Sikander Ailawadhi
Journal: Blood
Blood (2021) 138 (Supplement 1): 4078.
https://doi.org/10.1182/blood-2021-147955
Published: 2021
Journal Articles

The Epstein-Barr Virus Lytic Protein BZLF1 As a Candidate Target Antigen for Vaccine Development

Alex S. Hartlage, Tom Liu, PhD, John T. Patton, Sabrina L Garman, Xiaoli Zhang, PhD MS, Habibe Kurt, MD, Gerard Lozanski, MD, Mark E Lustberg, MD PhD, Michael A. Caligiuri, MD, Robert A. Baiocchi, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4144.
https://doi.org/10.1182/blood.V124.21.4144.4144
Published: 2014
Journal Articles

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia

Lisheng Wang, Jie Wang, Bradley W. Blaser, Anne-Marie Duchemin, Donna F. Kusewitt, Tom Liu, Michael A. Caligiuri, Roger Briesewitz
Journal: Blood
Blood (2007) 110 (6): 2075–2083.
https://doi.org/10.1182/blood-2007-02-071266
Published: 2007
Includes: Supplemental data